
Hong Sang
Examiner (ID: 14344, Phone: (571)272-8145 , Office: P/1643 )
| Most Active Art Unit | 1643 |
| Art Unit(s) | 1646, 1643 |
| Total Applications | 1298 |
| Issued Applications | 583 |
| Pending Applications | 145 |
| Abandoned Applications | 615 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17945796
[patent_doc_number] => 20220332813
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/712167
[patent_app_country] => US
[patent_app_date] => 2022-04-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28327
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17712167
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/712167 | COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE | Apr 2, 2022 | Pending |
Array
(
[id] => 17851932
[patent_doc_number] => 20220281974
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-09-08
[patent_title] => TREATMENT OF PD-L1-POSITIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY
[patent_app_type] => utility
[patent_app_number] => 17/701436
[patent_app_country] => US
[patent_app_date] => 2022-03-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19450
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17701436
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/701436 | TREATMENT OF PD-L1-POSITIVE MELANOMA USING AN ANTI-PD-1 ANTIBODY | Mar 21, 2022 | Pending |
Array
(
[id] => 19058998
[patent_doc_number] => 11938192
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-26
[patent_title] => Dosage regimes for the administration of an anti-CD19 ADC
[patent_app_type] => utility
[patent_app_number] => 17/699065
[patent_app_country] => US
[patent_app_date] => 2022-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 39799
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 125
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17699065
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/699065 | Dosage regimes for the administration of an anti-CD19 ADC | Mar 17, 2022 | Issued |
Array
(
[id] => 18213089
[patent_doc_number] => 20230059353
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-02-23
[patent_title] => ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/686920
[patent_app_country] => US
[patent_app_date] => 2022-03-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24402
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17686920
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/686920 | ANTIBODIES DIRECTED TO HER-3 AND USES THEREOF | Mar 3, 2022 | Abandoned |
Array
(
[id] => 18037569
[patent_doc_number] => 20220381785
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-01
[patent_title] => Cancer Detection Method
[patent_app_type] => utility
[patent_app_number] => 17/666143
[patent_app_country] => US
[patent_app_date] => 2022-02-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15107
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17666143
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/666143 | Cancer Detection Method | Feb 6, 2022 | Abandoned |
Array
(
[id] => 17611545
[patent_doc_number] => 20220153824
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => ANTI-C5A ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/591109
[patent_app_country] => US
[patent_app_date] => 2022-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20281
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17591109
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/591109 | ANTI-C5A ANTIBODIES AND USES THEREOF | Feb 1, 2022 | Abandoned |
Array
(
[id] => 19840167
[patent_doc_number] => 12252536
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-03-18
[patent_title] => Caninized antibodies
[patent_app_type] => utility
[patent_app_number] => 17/573870
[patent_app_country] => US
[patent_app_date] => 2022-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 10
[patent_no_of_words] => 29743
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 337
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17573870
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/573870 | Caninized antibodies | Jan 11, 2022 | Issued |
Array
(
[id] => 18108123
[patent_doc_number] => 20230001003
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-01-05
[patent_title] => MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/556863
[patent_app_country] => US
[patent_app_date] => 2021-12-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 51306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -22
[patent_words_short_claim] => 252
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17556863
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/556863 | MEDITOPES AND MEDITOPE-BINDING ANTIBODIES AND USES THEREOF | Dec 19, 2021 | Pending |
Array
(
[id] => 17929870
[patent_doc_number] => 20220324995
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-13
[patent_title] => ADAM9-Binding Molecules, and Methods of Use Thereof
[patent_app_type] => utility
[patent_app_number] => 17/553941
[patent_app_country] => US
[patent_app_date] => 2021-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38502
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 511
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17553941
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/553941 | ADAM9-Binding Molecules, and Methods of Use Thereof | Dec 16, 2021 | Abandoned |
Array
(
[id] => 17625714
[patent_doc_number] => 20220160729
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-26
[patent_title] => Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy
[patent_app_type] => utility
[patent_app_number] => 17/542712
[patent_app_country] => US
[patent_app_date] => 2021-12-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54786
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17542712
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/542712 | Replacement of Cytotoxic Preconditioning Before Cellular Immunotherapy | Dec 5, 2021 | Pending |
Array
(
[id] => 17609919
[patent_doc_number] => 20220152198
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-19
[patent_title] => METHODS AND COMPOSITIONS FOR TREATING CANCER AND INFECTIOUS DISEASES
[patent_app_type] => utility
[patent_app_number] => 17/533065
[patent_app_country] => US
[patent_app_date] => 2021-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16327
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17533065
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/533065 | METHODS AND COMPOSITIONS FOR TREATING CANCER AND INFECTIOUS DISEASES | Nov 21, 2021 | Pending |
Array
(
[id] => 17748237
[patent_doc_number] => 20220226440
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-21
[patent_title] => MODULATION OF CANCER IMMUNITY WITH TYPE 2 INNATE LYMPHOID CELLS, INTERLEUKIN 33, AND/OR INTERFERON INDUCED PROTEIN 44
[patent_app_type] => utility
[patent_app_number] => 17/531477
[patent_app_country] => US
[patent_app_date] => 2021-11-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24899
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17531477
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/531477 | MODULATION OF CANCER IMMUNITY WITH TYPE 2 INNATE LYMPHOID CELLS, INTERLEUKIN 33, AND/OR INTERFERON INDUCED PROTEIN 44 | Nov 18, 2021 | Abandoned |
Array
(
[id] => 17578843
[patent_doc_number] => 20220135698
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-05
[patent_title] => J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE
[patent_app_type] => utility
[patent_app_number] => 17/455097
[patent_app_country] => US
[patent_app_date] => 2021-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14616
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17455097
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/455097 | J591 MINIBODIES AND CYS-DIABODIES FOR TARGETING HUMAN PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) AND METHODS FOR THEIR USE | Nov 15, 2021 | Pending |
Array
(
[id] => 17533696
[patent_doc_number] => 20220112305
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-04-14
[patent_title] => Therapeutic Molecules
[patent_app_type] => utility
[patent_app_number] => 17/508583
[patent_app_country] => US
[patent_app_date] => 2021-10-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 43522
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17508583
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/508583 | Therapeutic molecules | Oct 21, 2021 | Issued |
Array
(
[id] => 17397997
[patent_doc_number] => 20220040087
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => AUGMENTATION OF PERSONALIZED TUMOR SPECIFIC ADAPTIVE IMMUNITY THROUGH EXTRACORPOREAL REMOVAL OF IMMUNE BLOCKING FACTORS
[patent_app_type] => utility
[patent_app_number] => 17/505100
[patent_app_country] => US
[patent_app_date] => 2021-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14283
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17505100
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/505100 | AUGMENTATION OF PERSONALIZED TUMOR SPECIFIC ADAPTIVE IMMUNITY THROUGH EXTRACORPOREAL REMOVAL OF IMMUNE BLOCKING FACTORS | Oct 18, 2021 | Abandoned |
Array
(
[id] => 17397998
[patent_doc_number] => 20220040088
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-02-10
[patent_title] => AUGMENTATION OF PERSONALIZED TUMOR SPECIFIC ADAPTIVE IMMUNITY THROUGH EXTRACORPOREAL REMOVAL OF IMMUNE BLOCKING FACTORS
[patent_app_type] => utility
[patent_app_number] => 17/505154
[patent_app_country] => US
[patent_app_date] => 2021-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14269
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17505154
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/505154 | AUGMENTATION OF PERSONALIZED TUMOR SPECIFIC ADAPTIVE IMMUNITY THROUGH EXTRACORPOREAL REMOVAL OF IMMUNE BLOCKING FACTORS | Oct 18, 2021 | Abandoned |
Array
(
[id] => 17643200
[patent_doc_number] => 20220170938
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-02
[patent_title] => COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER
[patent_app_type] => utility
[patent_app_number] => 17/470462
[patent_app_country] => US
[patent_app_date] => 2021-09-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54237
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 89
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470462
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/470462 | Compositions, methods and kits for diagnosis of lung cancer | Sep 8, 2021 | Issued |
Array
(
[id] => 17593635
[patent_doc_number] => 20220143208
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-05-12
[patent_title] => METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY
[patent_app_type] => utility
[patent_app_number] => 17/463156
[patent_app_country] => US
[patent_app_date] => 2021-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 21852
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463156
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/463156 | METHODS FOR INCREASING EFFICACY OF FOLR1 CANCER THERAPY | Aug 30, 2021 | Abandoned |
Array
(
[id] => 20143974
[patent_doc_number] => 12378301
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-08-05
[patent_title] => B1SP fusion protein therapeutics, methods, and uses
[patent_app_type] => utility
[patent_app_number] => 17/459905
[patent_app_country] => US
[patent_app_date] => 2021-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 33
[patent_figures_cnt] => 52
[patent_no_of_words] => 12821
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 20
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17459905
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/459905 | B1SP fusion protein therapeutics, methods, and uses | Aug 26, 2021 | Issued |
Array
(
[id] => 17290945
[patent_doc_number] => 20210386784
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-16
[patent_title] => CELLS AND METHODS FOR IMPROVED IMMUNOTHERAPY
[patent_app_type] => utility
[patent_app_number] => 17/412572
[patent_app_country] => US
[patent_app_date] => 2021-08-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13196
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17412572
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/412572 | CELLS AND METHODS FOR IMPROVED IMMUNOTHERAPY | Aug 25, 2021 | Pending |